Lunai Bioworks Inc (LNAI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.39+1.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LNAI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of — · Company calendar date is not available
LNAI — legal / regulatory event
Dated 2026-05-11
of the Original Report is hereby amended to include the following disclosures: On April 28, 2026, Lunai Bioworks, Inc. (the “ Company ”) received a staff determination letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) formally notifying the Company that, based upon its continued non-compliance with the $35,000,000 market value of listed securities (“ MVLS ”) requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “ MVLS Rule ”) upon the expiration o…
Why it matters: This split aims to raise the stock price above $1.00 for Nasdaq compliance. A successful outcome is crucial for maintaining the listing.
Supportive ifThe stock price stabilizes above $1.00 for at least 10 consecutive trading days post-split.
Worry ifThe stock price remains below $1.00 for more than 10 consecutive trading days after the split.
Why it matters: Smart use of capital will help growth. It will also boost investor trust after the deals.
Watch forManagement shares a clear plan for using capital to support growth.
Also watch forManagement does not give a clear plan for capital use, causing uncertainty.
Why it matters: Progress in this area could validate the company's approach and attract further funding. It’s a key growth area.
Supportive ifNew deals or funding for precision neurology have been announced.
Worry ifNo new partnerships or funding announcements in the next three months.
Why it matters: The first contract that makes money could lead to financial stability. This growth is key for the company's future.
Supportive ifRevenue from the defense contract is higher than expected.
Worry ifNo revenue is generated from the defense contract within the next quarter.
Why it matters: Staying compliant is key for Lunai's stock to stay on Nasdaq and keep investors confident.
Supportive ifLunai's stock price remains above $1.00 per share after the reverse split.
Worry ifStock price falls below $1.00 per share, risking delisting.
Why it matters: The meeting will decide on key proposals, including the reverse stock split. A successful vote is crucial for compliance with Nasdaq listing rules.
Supportive ifAt least 75% of votes cast support the reverse stock split proposal.
Worry ifLess than 50% of votes cast support the reverse stock split proposal.
Why it matters: A return to faster revenue growth could signal a turnaround in the business. It may improve investor confidence and outlook.
Supportive ifRevenue growth speeds up again, reaching over 10% year over year.
Worry ifRevenue growth continues to decelerate or stays below 10% year over year.
Why it matters: This report will provide insights into revenue growth and the impact of the reverse stock split.
Watch forThe earnings report shows revenue growth or good news in precision neurology.
Also watch forThe earnings report shows ongoing losses with no signs of improvement.
Why it matters: Finishing this deal could help Lunai Bioworks grow. It may improve how the market sees them.
Supportive ifA press release will confirm that Oncotelic and Pelerin are now part of Lunai Bioworks.
Worry ifThere are delays with the Oncotelic and Pelerin integration. There are also problems.
Why it matters: The lawsuit's result could help shareholders and affect stock performance.
Supportive ifCourt rulings that favor Lunai Bioworks in the discovery process.
Worry ifBad court decisions or delays that slow down the lawsuit.
Why it matters: This litigation aims to identify parties involved in short selling that hurt the stock price. The outcome could restore shareholder value.
Supportive ifDiscovery shows who was involved in unfair trading.
Worry ifNo important findings come from the lawsuit.
Why it matters: The meeting will decide on key proposals, including the reverse stock split. A successful vote is crucial for compliance with Nasdaq listing rules.
Supportive ifMost stockholders agree with the proposals at the Special Meeting.
Worry ifProposals do not get enough support, risking Nasdaq compliance.
Why it matters: The outcome will determine if Lunai Bioworks stays listed. A delisting could hurt investor confidence.
Worry ifThe Nasdaq Hearings Panel supports Lunai Bioworks. They can keep their listing.
Less concerning ifThe Nasdaq Hearings Panel confirms the delisting of Lunai Bioworks.
Why it matters: Successful compliance with Nasdaq rules is crucial for Lunai's stock to remain listed. Failure could lead to delisting.
Worry ifThe stock price stays above $1.00 per share for at least 30 consecutive trading days after the reverse split.
Less concerning ifThe stock price falls below $1.00 per share and stays there for 30 consecutive trading days.
Why it matters: Progress in biodefense can drive revenue and validate Lunai's strategic direction. Delays could hinder growth.
Supportive ifLook for new contracts or partnerships in biodefense beyond the first contract.
Worry ifNo new contracts or partnerships announced in the next quarter.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$355 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $1,315 loss on $10,000 · 13.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,170 loss on $10,000 · 91.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.